Real-World data shows MS Drug's impact on relapses and daily life

NCT ID NCT06251986

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study looked at how well the multiple sclerosis (MS) treatment ofatumumab (brand name Kesimpta) worked for people in everyday Spanish clinics, not just in controlled trials. It followed 310 adults with relapsing MS who had been on the treatment for at least a year. The main goal was to see how often patients had symptom flare-ups (relapses) and to check the treatment's safety and how well people stuck with it in real life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

Palma, Balearic Islands, 07120, Spain
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Santander, Cantabria, 39008, Spain
Novartis Investigative Site

Albacete, Castille-La Mancha, 02006, Spain
Novartis Investigative Site

Salt, Girona, 17190, Spain
Novartis Investigative Site

Logroño, La Rioja, 26006, Spain
Novartis Investigative Site

Fuenlabrada, Madrid, 28942, Spain
Novartis Investigative Site

Majadahonda, Madrid, 28222, Spain
Novartis Investigative Site

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site

Vigo, Pontevedra, 36212, Spain
Novartis Investigative Site

Santa Cruz, Santa Cruz de Tenerife, 38009, Spain
Novartis Investigative Site

Barakaldo, Vizcaya, 48903, Spain
Novartis Investigative Site

Alicante, 03010, Spain
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Burgos, 09006, Spain
Novartis Investigative Site

Cáceres, 10004, Spain
Novartis Investigative Site

Córdoba, 14004, Spain
Novartis Investigative Site

Granada, 18016, Spain
Novartis Investigative Site

León, 24080, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Madrid, 28040, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Madrid, 28046, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Seville, 41009, Spain
Novartis Investigative Site

Seville, 41013, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Novartis Investigative Site

Valencia, 46026, Spain
Novartis Investigative Site

Zaragoza, 50009, Spain

Conditions

Explore the condition pages connected to this study.

RELAPSING FORMS OF MULTIPLE SCLEROSIS